SARS-CoV-2 Nucleocapsid Monoclonal Antibody (3865), Invitrogen™

Description

• Specificity: Specific for the nucleocapsid of Covid-19 virus
• Cross reacts with SARS
• Non-reactive with: Influenza A, Influenza B, Adenovirus & MERS
• Reactive with the nucleocapsids of Variants: UK B.1.1.7, SA B.1.351, Brazil P.1, B.1.617.2 (Delta), B.1.1.529 (Omicron) & BA.7
• Purified preparations consist of >90% pure mouse monoclonal antibody which has been purified from ascites fluid by protein A chromatography
• The final preparation is formulated to a protein concentration of 100 μg/mL in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide
• Each vial contains 1.0 mL
• This product contains no stabilizing proteins and should be stored at 4C until ready for use
• Working dilution must be determined by the user
• Suggested starting ranges are 1:10-1:50 for ICC/IF and 1:20-1:200
• for ELISA
• SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid
• It is the most abundant protein for coronavirus
• Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus
• The SARS-CoV-2 N protein is an abundant RNA-binding protein critical for viral genome packaging, yet the molecular details that involve this process are poorly understood
• N protein contains three dynamic disordered regions that house putative transiently-helical binding motifs
• The two folded domains interact minimally such that full-length N protein is a flexible and multivalent RNA-binding protein
• SARS-CoV-2 causes illnesses ranging from the common cold to severe diseases.